| Quote
: |
刘源,张康乐,范仪铭,郭珈宜,李峰,郭艳幸.苍黄散外敷治疗兔早期膝骨关节炎的实验研究[J].湖南中医药大学学报英文版,2020,40(3):286-291.[Click to copy
] |
|
| |
|
|
| This paper
：Browser 1788times Download 467times |
| 苍黄散外敷治疗兔早期膝骨关节炎的实验研究 |
| 刘源,张康乐,范仪铭,郭珈宜,李峰,郭艳幸 |
| (湖南中医药大学, 湖南 长沙 410208;明光市中医院, 安徽 滁州 239400;河南省洛阳正骨医院, 河南 洛阳 471002) |
| 摘要: |
| 目的 观察平乐郭氏正骨苍黄散外敷治疗兔早期膝骨关节炎（knee osteoarthritis，KOA）滑膜组织的病理改变，以及软骨组织中白细胞介素-1β（interleukin-1 β，IL-1β）、肿瘤坏死因子-α（tumor necrosis factor，TNF-α）、金属蛋白酶-13（matrix metalloproteinase，MMP-13）的水平变化，探讨经验方苍黄散治疗早期KOA的作用机制。方法 将30只新西兰大白兔随机分为3组：平乐正骨苍黄散组（简称经验方组）、扶他林组、模型组，采用木瓜蛋白酶和半胱氨酸混合液兔关节腔内注射完成动物早期KOA造模，经验方组和扶他林组兔分别采用对应药物外敷治疗，治疗时间为20 d。治疗结束后记录每组兔膝关节局部皮肤温度，HE染色法观察关节滑膜组织，用ELISA和Westernblot方法检测软骨组织中IL-1β、TNF-α、MMP13含量及蛋白的表达量。结果 治疗结束后，经验方组和扶他林组皮温改善程度优于模型组，差异具有统计学意义（P<0.05）；病理学观察发现：模型组膝关节滑膜大量增生，并且可见血管增生明显，其他两组中膝关节滑膜组织中血管增生较少，少量炎性细胞浸润；模型组滑膜组织及软骨组织中IL-1β、TNF-α、MMP-13含量及蛋白表达量明显高于另外两组，差异明显（P<0.05），经验方组与扶他林组之间IL-1β、TNF-α、MMP-13含量及蛋白表达量，差异无统计学意义（P>0.05）。结论 平乐郭氏正骨经验方苍黄散外敷能缓解兔早期膝骨关节模型皮温高的症状，同时能降低软骨组织中IL-1β、TNF-α、MMP-13含量，此结果为临床运用提供了实验依据。 |
| 关键词: 膝骨关节炎 苍黄散 平乐正骨 白细胞介素-1β 肿瘤坏死因子-α 金属蛋白酶-13 |
| DOI：10.3969/j.issn.1674-070X.2020.03.008 |
| Received:September 18, 2019 |
| 基金项目:国家中医药管理局建设项目（〔2012〕228）；河南省科技厅项目（112102310008）；河南省中医药管理局项目（HNZYLJ20131009）；2017河南省中医药科学研究专项（2017ZY2085）。 |
|
| Experimental Research on External Application of Canghuang Powder in the Treatment of Early Knee Osteoarthritis in Rabbits |
| LIU Yuan,ZHANG Kangle,FAN Yiming,GUO Jiayi,LI Feng,GUO Yanxing |
| (Hunan University of Chinese Medicine, Changsha, Hunan 410208, China;Mingguang Municipal Hospital of Traditional Chinese Medicine, Chuzhou, Anhui 239400, China;Luoyang Orthopedic Traumatological Hospital, Luoyang, Henan 471002, China) |
| Abstract: |
| Objective To observe the pathological changes of synovial tissue in early knee osteoarthritis (KOA) treated with Pingle Guo's Bone-setting's Canghuang Powder external application, and the changes of interleukin-1β (IL-1β), tumor necrosis factor-α (TNF-α) and metalloproteinase-13 (MMP-13) levels in cartilage tissues, and to explore the mechanism of Canghuang Powder in treating early KOA. Methods A total of 30 New Zealand white rabbits were randomly divided into a Pingle bone-setting's Canghuang Powder group (experiential prescription group), a Votalin group and a model control group. The rabbits were injected with papain and cysteine mixture into articular cavity to complete early KOA model. The rabbits in the experiential prescription group and the Votalin group were treated with external application of corresponding drugs for 20 days. At the end of reatment, local skin temperature of knee joint was recorded, synovial tissue was observed by HE staining, and IL-1β, TNF-α, MMP13 content and protein expression in cartilage tissues were detected by ELISA and Western blot. Results After the treatment, the improvement of skin temperature in the empirical prescription group and the Votalin group was better than that in the model group, and the difference was statistically significant (P<0.05). Histopathological observation of synovium showed that the synovium of the knee joint in the model group had a large number of hyperplasia, and obvious vascular proliferation was seen. In the other two groups, synovial and vascular proliferation was less and inflammatory cell infiltration was small. The content and protein expression of IL-1β, TNF-α, MMP-13 in synovial tissue and cartilage tissue of the model group were significantly higher than those of other two groups (P<0.05). There was no significant difference in the content and protein expression of IL-1β, TNF-α, MMP-13 between the experiential prescription group and the Votalin group (P>0.05). Conclusion This study found that Pingle Guo's bone-setting's empirical prescription Canghuang Powder can alleviate the symptoms of high skin temperature in early knee joint model of rabbits, and reduce the contents of IL-1β, TNF-α and MMP-13 in synovial tissue and cartilage tissue, which provides a experimental basis for clinical application. |
| Key words: knee osteoarthritis Canghuang Powder Pingle Bone-setting IL-1β TNF-α MMP-13 |
|
二维码（扫一下试试看！） |
|
|
|
|
